Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Hepatocyte growth factor (HGF) or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells and T cells. It has been shown to have a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration, and in wound healing.
The harvesting, processing, and consuming of seafoods are ancient practices with archaeological evidence dating back well into the Paleolithic. Findings in a sea cave at Pinnacle Point in South Africa indicate Homo sapiens (modern humans) harvested marine life as early as 165,000 years ago, while the Neanderthals, an extinct human species contemporary with early Homo sapiens, appear to have been eating seafood at sites along the Mediterranean coast beginning around the same time. Isotopic analysis of the skeletal remains of Tianyuan man, a 40,000-year-old anatomically modern human from eastern Asia, has shown that he regularly consumed freshwater fish. Archaeology features such as shell middens, discarded fish bones, and cave paintings show that sea foods were important for survival and consumed in significant quantities. During this period, most people lived a hunter-gatherer lifestyle and were, of necessity, constantly on the move. However, early examples of permanent settlements (though not necessarily permanently occupied), such as those at Lepenski Vir, were almost always associated with fishing as a major source of food. The ancient river Nile was full of fish; fresh and dried fish were a staple food for much of the population. The Egyptians had implements and methods for fishing and these are illustrated in tomb scenes, drawings, and papyrus documents. Some representations hint at fishing being pursued as a pastime.
==== Direct killing of cancer cells ==== Malignant cells are vulnerable to SeV infection. Sendai virus can infect and kill variable cancer cells (see section Sensitive cell lines and virus strains). However, some malignant cells are resistant to SeV infection. There are multiple explanations for such resistance. Not all cancer cells have cell entry receptors for the virus and not all cancer cells express virus processing serine proteases. There are also other mechanisms that can make a cancer cell resistant to an oncolytic virus. For example, some cancer cells maintain interferon response system that completely or partially protects a host cells from a virus infection. Therefore, biomarkers needed to be developed to identify tumors that might succumb to SeV mediated oncolysis.
== Description == The sucrose lysis test uses an isotonic sucrose solution to lower the ionic strength of serum, which triggers the activation of the classic complement pathway, leading to the lysis of cells that are sensitive to complement. In the sucrose lysis test, patient RBCs are washed and resuspended in a buffered sucrose solution. The solution is then incubated at a set temperature for a specified period, during which complement-mediated lysis occurs. After incubation, the solution is centrifuged, and the amount of hemoglobin released is measured spectrophotometrically. The degree of lysis is compared to that of control samples. Although more sensitive than the Ham test, it is not as specific since some RBCs hemolyze to a minor degree in autoimmune hemolytic anemias, leukemia, and aplastic anemia. Although affordable and straightforward to perform, the test is more labor-intensive because PNH RBCs have a short half-life in circulation.
The following is a list of antibiotics. The highest division between antibiotics is bactericidal and bacteriostatic. Bactericidals kill bacteria directly, whereas bacteriostatics prevent them from dividing. However, these classifications are based on laboratory behavior. The development of antibiotics has had a profound effect on the health of people for many years. Also, both people and animals have used antibiotics to treat infections and diseases. In practice, both treat bacterial infections.
Sources: en.wikipedia.org
== External links == GeneReviews/NCBI/NIH/UW entry on Ehlers-Danlos Syndrome, Hypermobility Type This article incorporates text from the United States National Library of Medicine, which is in the public domain.
== Overview == General Blood was founded by David Mitchell and Ben Bowman, who both received MBA’s from the Carlson School of Management at the University of Minnesota. Bowman began researching the blood distribution industry in 2007 while still enrolled in the MBA program. General Blood LLC was created in 2010 and is headquartered in downtown Minneapolis, Minnesota on the Mississippi River. Ben Bowman is chief executive officer at General Blood, and David Mitchell is the executive vice president. In 2013, General Blood was an exhibitor for the Clinical Laboratory Management Association. In 2012, General Blood was a Minnesota Cup Semi-Finalist in the Bio-Science and Health IT Division.
During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Trinoid #0 Saunaginnan resurrects Ben G, who is subsequently killed by Deka Master, Pink, and Break, as well as Abare Killer. Ben G is voiced by Nobuyuki Hiyama (檜山 修之, Hiyama Nobuyuki). Cristonian Ferley (クリスト星人ファーリー, Kurisuto Seijin Fārī): A werewolf/vampire bat–themed criminal from Planet Cristo who is charged with burglary and murdering several S.P.D. officers. As his body is photosensitive, he tasks a Batsuroid with piloting a Kaijuki called Devil Capture 4 (デビルキャプチャー4, Debiru Kyapuchā Fō) to distract the Dekarangers while Ferley locates and eats a mineral called Lunar Metal so he can roam freely in daylight. Devil Capture 4 is destroyed by Dekaranger Robo while Ferley is deleted by the Dekarangers via the D-Bazooka. In the direct-to-video special Tokusou Sentai Dekaranger Super Video: Super Finisher Match! Deka Red vs. Deka Break, a variation of Ferley called Burning Ferley (バーニング・ファーリー, Bāningu Fārī) appears as part of a simulation training session. Ferley is voiced by Hisao Egawa (江川 央生, Egawa Hisao). Titarnian Metiussl (ティタン星人メテウス, Titan Seijin Meteusu): A brutal flame/astronaut–themed criminal and self-proclaimed "Destroyer King" (破壊王, Hakaiō) from Planet Titarn who seeks out an android girl named Flora, whom he created to control his giant creation Machine Monster Gigas (マシンモンスター・ギーガス, Mashin Monsutā Gīgasu). He tasks a Batsuroid with piloting a gladiator-themed Kaijuki called Cannon Gladiator (キャノングラディエーター, Kyanon Guradiētā) and attacking the Deka Base while he locates Flora.
=== Viral trends === The app has spawned numerous viral trends, Internet celebrities, and music trends around the world. Duets, a feature that allows users to add their own video to an existing video with the original content's audio, have sparked many of these trends. Many stars got their start on Musical.ly, which merged with TikTok on 2 August 2018. These include Loren Gray, Baby Ariel, Zach King, Lisa and Lena, Jacob Sartorius, and many others. Loren Gray remained the most-followed individual on TikTok until Charli D'Amelio surpassed her on 25 March 2020. Gray's was the first TikTok account to reach 40 million followers on the platform. She was surpassed with 41.3 million followers. D'Amelio was the first to ever reach 50, 60, and 70 million followers. Charli D'Amelio remained the most-followed individual on the platform until she was surpassed by Khaby Lame on 23 June 2022. Other creators rose to fame after the platform merged with musical.ly on 2 August 2018. TikTok also played a major part in making "Old Town Road" by Lil Nas X one of the biggest songs of 2019 and the longest-running number-one song in the history of the US Billboard Hot 100. TikTok has allowed many music artists to gain a wider audience, often including foreign fans. For example, despite never having toured in Asia, the band Fitz and the Tantrums developed a large following in South Korea following the widespread popularity of their 2016 song "HandClap" on the platform.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.